Riya Gandhi, MA

contact dermtitis + Neck + Eczema + rash
News
Dupilumab Therapy Reduces Systemic Inflammation in Prurigo Nodularis
02/14/2025
A study highlights the broad anti-inflammatory effects of dupilumab in prurigo nodularis, with potential implications for addressing systemic disease comorbidities.
A study highlights the broad anti-inflammatory effects of dupilumab in prurigo nodularis, with potential implications for addressing systemic disease comorbidities.
A study highlights the broad...
02/14/2025
APP Institute Dermatology
Atopic dermatitis
Quiz
Understanding Type 2 Inflammation: Pathways and Treatment Options
02/07/2025
Test your knowledge of type 2 Inflammation and your understanding of its pathways and treatment options.
Test your knowledge of type 2 Inflammation and your understanding of its pathways and treatment options.
Test your knowledge of type 2...
02/07/2025
APP Institute Dermatology
Clinical Insights
Addressing Inflammatory Skin Conditions in Diverse Populations
02/03/2025
There is a wide spectrum of considerations when diagnosing and treating patients with skin of color who present with inflammatory skin conditions.
There is a wide spectrum of considerations when diagnosing and treating patients with skin of color who present with inflammatory skin conditions.
There is a wide spectrum of...
02/03/2025
The Dermatologist
NAAF-Reviewed Content
Managing Pediatric Alopecia Areata: Part 2
02/03/2025
Although there is no one-size-fits-all approach, alopecia areata is becoming a treatable disease in children and adolescents.
Although there is no one-size-fits-all approach, alopecia areata is becoming a treatable disease in children and adolescents.
Although there is no...
02/03/2025
The Dermatologist
SOC
News
Immune Triggers Linked to Chronic Pruritus and Elevated Type 2 Inflammation
01/29/2025
New findings uncover the role of immune triggers, including vaccines and therapies, in chronic pruritus and its association with heightened type 2 inflammation markers.
New findings uncover the role of immune triggers, including vaccines and therapies, in chronic pruritus and its association with heightened type 2 inflammation markers.
New findings uncover the role of...
01/29/2025
APP Institute Dermatology
News
Upadacitinib Demonstrates Significant Improvement in Enthesitis in Psoriatic Arthritis Patients
01/20/2025
A post hoc analysis of the SELECT-PsA trials shows that upadacitinib significantly improves enthesitis, with sustained benefits and protection from recurrence or new-onset enthesitis in psoriatic arthritis patients.
A post hoc analysis of the SELECT-PsA trials shows that upadacitinib significantly improves enthesitis, with sustained benefits and protection from recurrence or new-onset enthesitis in psoriatic arthritis patients.
A post hoc analysis of the...
01/20/2025
Rheumatology & Arthritis
News
TNF Inhibitor Treatment Reduces Fracture Risk in Axial Spondyloarthritis
01/20/2025
A study of more than 13,000 individuals with axial spondyloarthritis reveals that treatment with TNF inhibitors may significantly lower the risk of hip and spine fractures compared to traditional NSAIDs.
A study of more than 13,000 individuals with axial spondyloarthritis reveals that treatment with TNF inhibitors may significantly lower the risk of hip and spine fractures compared to traditional NSAIDs.
A study of more than 13,000...
01/20/2025
Rheumatology & Arthritis
News
Statins Mitigate Risk With Tofacitinib in RA Patients with ASCVD
01/20/2025
A new analysis highlights the role of statins in reducing major cardiovascular events in high-risk rheumatoid arthritis patients treated with tofacitinib.
A new analysis highlights the role of statins in reducing major cardiovascular events in high-risk rheumatoid arthritis patients treated with tofacitinib.
A new analysis highlights the...
01/20/2025
Rheumatology & Arthritis
Atopic dermatitis
News
Dupilumab Linked to Lower Risk of Upper Respiratory Infections in Patients With Atopic Dermatitis
01/17/2025
New research highlights the safety benefits of dupilumab over traditional immunosuppressants in reducing upper respiratory infection risks for patients with moderate-to-severe atopic dermatitis.
New research highlights the safety benefits of dupilumab over traditional immunosuppressants in reducing upper respiratory infection risks for patients with moderate-to-severe atopic dermatitis.
New research highlights the...
01/17/2025
APP Institute Dermatology
Atopic dermatitis
News
New Screening Tool Promotes Multidisciplinary Approach to Type 2 Inflammation-Related Diseases
01/07/2025
A groundbreaking questionnaire aims to address the unmet need for timely detection and referral of coexisting type 2 inflammation-related diseases, bridging gaps in interdisciplinary care.
A groundbreaking questionnaire aims to address the unmet need for timely detection and referral of coexisting type 2 inflammation-related diseases, bridging gaps in interdisciplinary care.
A groundbreaking questionnaire...
01/07/2025
APP Institute Dermatology

Upcoming Events

February 22 ⁠–⁠ February 23
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
WoundCon
March 21
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
March 29 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Psych Congress Regionals
April 3 ⁠–⁠ April 4
Advances in Inflammatory Bowel Disease Regionals
April 5 ⁠–⁠ April 6
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use